Author

A. C. Adams

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Organism:non-human primate· 1 Assay:proteomics· 1

Frequent Co-Authors

A. M. Macy· 2 shared K. T. Hastings· 2 shared A. A. L. Gunatilaka· 1 shared A. Charos· 1 shared A. Hughes· 1 shared A. Pustilnik· 1 shared A. R. Mangold· 1 shared A. R. Sertil· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. M. Macy

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Distinct sets of molecular characteristics define tumor-rejecting neoantigens

A. C. Adams, A. M. Macy, E. S. Borden, L. M. Herrmann, C. A. Brambley, T. Ma, X. Li, A. Hughes, D. J. Roe, A. R. Mangold, K. H. Buetow, M. A. Wilson, B. M. Baker, K. T. Hastings

The paper identifies molecular features of tumor-rejecting neoantigens in cSCC and shows how they differ from non-immunogenic neoantigens.

bioRxiv · Feb 13, 2024Immunology

Physachenolide C induces complete regression of established murine melanoma tumors via apoptosis and cell cycle arrest

A. C. Adams, A. M. Macy, P. Kang, K. F. Castro-Ochoa, E. M. K. Wijeratne, Y.-M. Xu, M. X. Liu, A. Charos, M. W. Bosenberg, A. A. L. Gunatilaka, A. R. Sertil, K. T. Hastings

This study shows that physachenolide C induces complete regression of established murine melanoma tumors through apoptosis and cell cycle arrest, with durable responses in some mice.

bioRxiv · May 27, 2021Cancer Biology

LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection

B. E. Jones, P. L. Brown-Augsburger, K. S. Corbett, K. Westendorf, J. Davies, T. P. Cujec, C. M. Wiethoff, J. L. Blackbourne, B. A. Heinz, D. Foster, R. E. Higgs, D. Balasubramaniam, L. Wang, R. Bidshahri, L. Kraft, , M. de Vries

LY-CoV555, an anti-spike antibody from a convalescent COVID-19 patient, neutralizes SARS-CoV-2 and protects non-human primates against infection.

bioRxiv · Sep 30, 2020Immunology